VAUGHAN, Ontario & IRVINE, Calif. –( BUSINESS WIRE )–Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc. (“AcuFocus”), a privately held ophthalmic medical device organization, today announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to the merger transaction with the parent company of AcuFocus.
AcuFocus has delivered breakthrough small aperture intraocular technology in order to address the diverse unmet needs in eye care, including the particular IC-8 ® Apthera ™ intraocular lens (IOL), which was approved by the U. S. Food and Drug Administration in July 2022 as the first and only small aperture non-toric extended depth associated with focus (EDOF) IOL for certain cataract patients who have as much as 1. 5 diopters of corneal astigmatism plus wish to address presbyopia at the same time. Known as the IC-8 IOL in global markets, this IOL is available in select markets across Europe, as well as in Australia, New Zealand and Singapore.
Cataracts are a common condition affecting an estimated 94 million people globally. one In fact, the global premium cataract IOL market is projected to grow at a compounded annual growth rate of approximately 13 percent between 2022 and 2027. 2 In the United States alone, approximately 24 million individuals have cataracts, a number that is expected to grow to 50 million by 2050. 3
Cataracts can only be treated with surgery in which the cloudy natural lens is removed and an IOL is implanted. 4 Many individuals receive a monofocal IOL at the time of cataract surgery, which may correct for distance vision, but not for presbyopia. Some available presbyopia-correcting IOLs have complex optics that split, shift or stretch light to provide clear vision at more than one discrete focal point. In contrast, the IC-8 Apthera IOL features proprietary small aperture technology that will enables both distance eyesight correction plus near vision correction in order to mitigate the effects of presbyopia.
“ Cataracts are the largest contributor to worldwide blindness in adults aged 50 years and older, with more than 15 million individuals, or around 45 % of the particular more than 33 million cases of global blindness. 5 We believe that the IC-8 Apthera EDOF IOL will bolster our surgical portfolio simply by enhancing our IOL offerings, which is a strategic area of focus for Bausch + Lomb, ” said Joseph C. Papa, CEO, Bausch + Lomb. “ All of us will continue to focus on areas of unmet medical need that we believe will help drive long-term growth in our core segments, and importantly, help us achieve our mission of helping people see better to reside better. ”
” Bausch + Lomb is a legacy name within eye care with a fully integrated portfolio of products in vision health, ” said Al Waterhouse, president and TOP DOG, AcuFocus. “ With its extensive development footprint and renowned commercial expertise, we think Bausch + Lomb is best positioned to educate physicians about the IC-8 Apthera lens, plus ultimately, ensure more cataract patients have access to this new IOL. ”
About the IC-8 Apthera IOL
The IC-8 Apthera IOL is the wavefront-filtering intraocular lens for unilateral implantation in sufferers who have been diagnosed with bilateral operable cataracts, have just as much as 1. 5 diopters of corneal astigmatism in the particular implanted eye and who do not have a history associated with retinal disease and are not predisposed to experience retinal disease in the future. This IOL, compared to the monofocal or monofocal toric IOL, provides an extended range of vision from distance through near.
As with any cataract surgery, risks associated with complications exist whether or not the IOL is incorporated. The complications of IOL implantation surgical treatment range from minor side effects (usually temporary) to serious problems. Patients with a history of previous illnesses or even disorders of the attention may possess a higher risk associated with complications. Patients with a history of retinal disease or those susceptible to retinal disease must not be implanted using the IOL. As with other prolonged depth of focus IOLs, further surgical treatment (such as IOL replacement for a different lens) may be needed after implantation of the IOL.
A full list of benefits and risks associated with the IC-8 Apthera IOL will be available within the Directions For Use plus the Patient Information Brochure.
BofA Securities served because exclusive financial advisor in order to AcuFocus in this transaction. Norton Rose Fulbright US LLP served since legal advisor to Bausch + Lomb, and Latham & Watkins LLP served as legal advisor to AcuFocus.
About AcuFocus, Inc.
AcuFocus, Incorporation. delivers breakthrough small aperture intraocular products to tackle diverse unmet needs inside eye treatment and assist patients accomplish their best personal vision. The IC-8 Apthera IOL (known since the IC-8 IOL in global markets) is approved in the United States with regard to the treatment of cataracts. The particular lens received CE mark in 2015 and is available in Australia, New Zealand, Singapore, and select marketplaces across European countries.
About Bausch + Lomb
Bausch + Lomb will be dedicated in order to protecting plus enhancing the particular gift associated with sight regarding millions of people around the world – through the moment of birth through every phase of life. Its comprehensive profile of more than 400 products includes contact lenses, zoom lens care products, eyesight maintenance systems, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial impact with more than 12, 000 employees and a presence in nearly 100 countries. Bausch + Lomb is usually headquartered within Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us upon Twitter , LinkedIn , Facebook plus Instagram .
This news release may contain “forward-looking statements” within the meaning associated with Section 27A of the Investments Act of 1933, as amended (the “Securities Act”), Section 21E from the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and “forward-looking information” under Canadian securities laws (collectively, “forward-looking statements”). These forward-looking statements include, but, but are usually not limited to, statements regarding AcuFocus’, Bausch + Lomb’s and their respective management teams’ expectations, hopes, beliefs, intentions plus strategies concerning the future. Statements that are not historical facts, including statements about the parties’ perspectives and expectations, are usually forward-looking claims. Forward-looking statements may generally be identified by the particular use associated with the words “anticipates, ” “hopes, ” “expects, ” “intends, ” “plans, ” “should, ” “could, ” “would, ” “may, ” “believes, ” “estimates, ” “potential, ” “target, ” or even “continue” plus variations or similar expressions, but the absence of these words does not mean that a statement is definitely not forward-looking. These statements are based upon the current expectations and beliefs of management associated with both AcuFocus and Bausch + Lomb and are subject to certain risks plus uncertainties that could cause actual results to differ materially from those described within the forward-looking statements. These types of risks and uncertainties include, but are not limited in order to, the risks plus uncertainties discussed in Bausch + Lomb’s respective filings with all the SEC and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any kind of these types of forward-looking claims. These forward-looking statements speak only while of the date hereof. Neither AcuFocus nor Bausch + Lomb undertakes any obligation to update any of these forward-looking statements to reflect events or even circumstances after the date of this news release or to reveal actual outcomes, unless required by law.
- The World Health Organization: Blindness and Vision impairment . Retrieved Dec. 12, 2022.
- Market Scope. 2022 IOL Market Report (April 2022).
- National Eye Institute. NEI charts the clearer future for cataract prevention and treatment . Retrieved December. 12, 2022.
- National Vision Institute. Cataracts . Retrieved Jan. 14, 2023.
- Steinmetz, J. D., Bourne, R. R., Briant, P. S., Flaxman, H. R., Taylor, H. L., Jonas, J. B.,… & Morse, The. R. F. (2021). Causes of blindness plus vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. The Lancet Global Wellness, 9(2), e144-e160. https://doi.org/10.1016/S2214-109X(20)30489-7
All products/brand names are trademarks of the respective owners.
© 2023 Bausch & Lomb Incorporated or its affiliates.